Dimensional Fund Advisors
ADAP

Dimensional Fund Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Dimensional Fund Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-88,580
Closed -$82K – 3468
2023
Q2 		$82K Buy
+88,580
New +$106K ﹤0.01% 3350

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors's ADAP Position: Q3 2023 in Review

Dimensional Fund Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 88,580 shares — an estimated $82K sold.

Dimensional Fund Advisors first reported a position in ADAP in Q2 2023 and held it in 1 quarter. The position peaked at $82K in Q2 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • Dimensional Fund Advisors reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 88,580 Adaptimmune Therapeutics shares in Q3 2023, an estimated $82K.
  • Dimensional Fund Advisors first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 1 quarter.
  • Dimensional Fund Advisors's Adaptimmune Therapeutics position peaked at $82K in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on Dimensional Fund Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.